Terminal differentiation of blood cells requires the concerted action of a series of transcription factors that are expressed at specific stages of maturation and function in a cell-type and dosage-dependent manner. Leukemogenic oncoproteins block differentiation by subverting the normal transcriptional status of hematopoietic precursor cells. Pirin (PIR) is a putative transcriptional regulator whose expression is silenced in cells bearing the acute myeloid leukemia-1 eight-twenty-one (AML1/ETO) and promyelocytic leukemia/retinoic acid receptor (PML/RAR) leukemogenic fusion proteins. A role for PIR in myeloid differentiation has not to date been reported. In this study we show that PIR expression is significantly repressed in a large proportion of acute myeloid leukemias (AMLs), regardless of subtype or underlying karyotypic abnormalities. We show that PIR expression increases during in vitro myeloid differentiation of primary hematopoietic precursor cells, and that ablation of PIR in the U937 myelomonocytic cell line or in murine primary hematopoietic precursor cells results in impairment of terminal myeloid differentiation. Gene expression profiling of U937 cells after knockdown of PIR revealed increased expression of genes associated with the early phases of hematopoiesis, in particular, homeobox A (HOXA) genes. Our results suggest that PIR is required for terminal myeloid maturation, and its downregulation may contribute to the differentiation arrest associated with AML.
Introduction
Hematopoietic differentiation is a multistage process in which pluripotent self-renewing hematopoietic stem cells give rise to all blood cell lineages and involves successive stages of commitment and maturation. As cells progress through the differentiation cascade, they acquire specific functions and lose self-renewal capacity through selective activation and silencing of a set of genes. These gene expression programs are triggered by both extrinsic and intrinsic signals, and are controlled by the orchestrated action of a series of transcription factors whose temporal and cell-type-specific expression is critical for their unique functions. 1 Acute myeloid leukemias (AMLs) are characterized by the expansion of myeloid precursors blocked at a specific stage of differentiation. The central role for transcription factor abnormalities in determining AML is supported by the high frequency of genetic alterations involving the corresponding genes, including chromosomal translocations and point mutations. Deregulated expression or structural abnormalities of these transcription factors subverts normal differentiation, and can ultimately lead to leukemogenesis. 2 Many studies have addressed the analysis of global gene expression in AML, but a clear identification of the specific effectors of the differentiation block that characterizes AML is still lacking. We previously analyzed the gene expression profile of U937 cells expressing the AML-associated fusion proteins, promyelocytic leukemia/retinoic acid receptor (PML/RAR), acute myeloid leukemia-1/eight-twenty-one (AML1/ETO) and promyelocytic leukemia zinc-finger/RAR, with the aim of identifying transcriptional targets involved in leukemogenesis and found upregulation of genes involved in stem cell maintenance and repression of differentiation-associated genes. 3 However, many of the genes strongly deregulated by the fusion proteins were poorly characterized and had no obvious functional link with hematopoiesis or leukemogenesis.
Pirin (PIR) is a highly conserved nuclear protein, originally isolated as an interactor of the nuclear factor I/CCAAT box transcription factor. 4 Although its function has not been fully elucidated, a role for PIR in transcriptional regulation has been proposed on the basis of its interaction with nuclear factor I/CCAAT box transcription factor as well as with the protooncoprotein B-cell chronic lymphocytic leukemia/lymphoma 3, 5 a member of the IkB family that modulates the activities of nuclear factor (NF)-kB/Rel transcription factors. 6 PIR is a member of the functionally diverse cupin family of proteins, 7 and has been shown to possess quercetinase enzymatic activity. 8 Other studies have linked PIR with different functions, such as apoptosis 9, 10 and response to stress, 11 and suggest a cell-type and species-specific activity.
PIR expression is silenced by both PML/RAR and AML1/ETO in U937 cells as well as in blasts from patients bearing the corresponding t(15;17) and t(8;21) translocations. 3 On the basis of its putative function as a transcriptional regulator, we decided to further analyze PIR expression in AML, and to functionally assess the effect of PIR silencing in hematopoietic cells. In this study we show that PIR downregulation is very frequent in AML, with no correlation with specific disease subtype or underlying genetic abnormality. Furthermore, PIR knockdown by short hairpin RNA (shRNA) results in incomplete maturation of both established (U937) and primary hematopoietic cells, suggesting that its silencing may be instrumental in the differentiation block that characterizes AML.
Materials and methods

Acute myeloid leukemia (AML) samples
The AML-M3 cases were kindly provided by Professor Francesco Lo Coco (University of Rome, Tor Vergata, Rome, Italy); all cases of subtypes other than M3 are de novo AML (age 15-60 years) from the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) LAM 99P and GIMEMA/European Organization for Research on Treatment of Cancer AML12 trials; all cases showed 470% of bone marrow infiltration by leukemic cells and have been characterized for subcellular nucleophosmin localization, karyotype, reverse transcription-PCR for major fusion transcripts, mixed lineage leukemia status and FMS-like tyrosine kinase 3 mutations. CD34 þ cells purified from healthy donors were obtained from Professor Antonio Tabilio (University of Perugia, Italy) and Professor Carmelo Carlo-Stella (Istituto Nazionale dei Tumori, Milan, Italy).
Quantitative real-time PCR (qPCR)
Total RNAs were extracted using RNeasy Mini Kit (QIAGEN, Valencia, CA, USA) and complementary DNA synthesis was performed using the Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instructions. TaqMan Gene Expression Assay Hs01125825_m1 for human PIR was included in a low-density array (Applied Biosystems, Foster City, CA, USA) for high-throughput screening of AML blasts. Analysis of homeobox (HOX) gene expression in U937-pSICO and U937-shPIR cell lines was performed using the following TaqMan Gene Expression Assays: Hs00601076_m1 for HOXA3; Hs00430330_m1 for HOXA5; Hs00600844_m1 for HOXA7; Hs00600844_m1 for HOXA9; and Hs00426284_m1 for HOXA13.
Cell culture and differentiation U937 and NB4 cells were grown in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 2 mM glutamine. U937 clones expressing AML1/ETO and PML/RAR have been described elsewhere. 3 For differentiation experiments, U937 cells were treated with vitamin D3 (250 ng/ml) and transforming growth factor-b (1 ng/ml), and NB4 cells were treated with retinoic acid (RA) 10 À6 M. Cells were harvested at the indicated time points and stained with the anti-CD14 antibody (Covance, Princeton, NJ, USA, for U937) or antiCD11b antibody (BD Pharmingen, San Diego, CA, USA, for NB4). Samples were acquired with FacsCalibur (FACSCanto II, Becton Dickinson, Franklin Lakes, NJ, USA). 293T cells, obtained from American Type Culture Collection center, were grown in Dulbecco's modied Eagle's medium supplemented with 10% FBS and 2 mM glutamine.
Generation of rabbit polyclonal anti-PIR antibody
PIR full-length coding sequence was inserted downstream to the glutathione S-transferase sequence in pGEX-4T1 vector (Amersham Pharmacia Biotech, Uppsala, Sweden) and after rabbit immunization with the glutathione S-transferase-PIR fusion protein, total antiserum was antigen-purified and eluted at a concentration of 440 mg/ml.
Western blot
Cells were lysed in JS buffer (50 mM Hepes, 150 mM sodium chloride, 1% glycerol, 1% Triton X-100, 1.5 mM magnesium chloride and 5 mM EDTA), 30-50 mg of extracts were loaded onto polyacrylamide gels for electrophoresis and proteins were transferred to nitrocellulose filter (Whatman, Kent, UK). Western blots were revealed using the enhanced chemiluminescence method (Amersham Biosciences, Fairfield, CT, USA). Antibodies used in this study were: anti-PIR (concentration 1 in 5000), antiactin AC-40 and anti-vinculin hVIN1 (both from Sigma-Aldrich, St Louis, MO, USA, 1 in 10 000).
PIR short hairpin RNA (shRNA) Short hairpin RNA constructs were generated using the pSICO-R-PGK-puro lentiviral vector that constitutively expresses the shRNA oligonucleotides and puromycin selection gene under control of PGK promoter. The following pairs of shRNA-forming sequences were annealed and cloned into the vector backbone:
Human Lentiviruses were packaged by transfection of pSICO-R together with the helper vectors in 293T cells; 12 the supernatant was concentrated, filtered and added to the target cells in the presence of polybrene. U937 cells underwent spin infection at 1800 r.p.m. for 1 h at 32 1C thrice, followed by puromycin selection (0.75 mg/ml). For lineage minus (LinÀ) cells, the viral supernatant was concentrated by ultra-centrifugation at 26 000 r.p.m. for 90 min at 4 1C before infection. LinÀ cells underwent two cycles of infection in complete medium in 24-well retronectin-coated (Takara-Shuzo, Shiga, Japan), nontissue culture-treated plates by incubation for 4 h at 37 1C, followed by puromycin selection (3 mg/ml).
Isolation of lineage minus (LinÀ) cells from mouse bone marrow
Lineage minus cells were purified from the bone marrow of 8-to 12-week-old 129SvEv mice. After Histopaque 1083 (SigmaAldrich) density separation, bone marrow mononucleated cells were enriched for stem and progenitor cells by depletion of differentiated cells using commercially available reagents (Stem Cell Technologies, Vancouver, BC, Canada). Cells were cultured in RPMI-1640 medium containing 10% FBS, interleukin 3 (IL-3, 20 ng/ml), IL-6 (20 ng/ml) and stem cell factor (SCF, 100 ng/ml cytokines from PeproTech, Rocky Hill, NJ, USA).
Lineage minus (LinÀ) differentiation assays in methylcellulose
shPIR and control LinÀ cells were plated (5000 cells per plate) in methylcellulose medium (Methocult SF M3236, Stem Cell Technologies) containing FBS and the following cytokines: IL-3 (2 ng/ml), IL-6 (2 ng/ml), SCF (50 ng/ml), granulocyte colonystimulating factor (G-CSF; 50 ng/ml) and granulocyte-macrophage CSF (GM-CSF; 10 ng/ml; all from PeproTech). At 7-10 days after plating, colonies were scored, and cells were harvested for western blotting and for morphological examination. Fluorescence-activated cell sorting (FACS) analysis of Mac1, Gr1, Sca-1 and c-Kit expression was performed using murine antibodies (Pharmingen BD, San Jose, CA, USA). Cells were analyzed by a Becton Dickinson FacsCalibur, using CellQuest software.
CD34 þ cell differentiation
CD34 þ cells were obtained from healthy donors (stimulated with G-CSF) and isolated from leukaphereses using the EasySep magnetic positive selection procedure (StemCell, Vancouver, BC, Canada). CD34 þ cell differentiation was carried out both in liquid and in semisolid medium. Methylcellulose medium (GF þ H4535), formulated to support growth of granulocytemacrophage progenitors was purchased from Stem Cells Technologies. A total of 2000 cells per 35 mm dish were seeded in triplicate. Colonies were harvested and cells were lysed for qPCR and western blotting after 9 days. For differentiation in liquid culture, cells were maintained for 12 days at 250-300 000/ml in Iscove's modified Dulbecco's medium supplemented with FBS and IL-6, SCF, Flt3 ligand, thrombopoietin, G-CSF and GM-CSF, each at 50 ng/ml. At day 9, 10% human serum was added to the medium.
RNA extraction, Affymetrix GeneChip hybridization and analysis
Total RNA was extracted using the RNeasy Mini Kit (QIAGEN). For each of the U937 cell lines (pSICO and shPIR 7), three independent RNA extractions were performed, and an equal quantity of each of the three RNA preparations was then mixed to generate an RNA pool for each sample. Biotin-labeled cRNA targets were obtained from 5 mg of each RNA pool using Affymetrix custom kit (Affymetrix, Santa Clara, CA, USA). GeneChip hybridization, washing, staining and scanning were performed according to Affymetrix protocols. Two copies of the HG-U133 Plus 2.0 array were hybridized with each target. Data derived from U937-shPIR 7 cells (sample) were compared with those of U937-pSICO cells (baseline) by 'comparative analysis' with GeneChip Operating software, and further analyzed using GenePicker software 13 as previously described, 3,14 using a fold change cutoff of 42 and a Pvalue of 0.05. Functional classification of lists of regulated probe sets was performed using Ingenuity's Ingenuity pathways analysis (IPA) version 7.5-2202 software (Ingenuity Systems, www.ingenuity.com, Redwood City, CA, USA). Genes from the data set that met the fold change cutoff of two and were associated with biological functions and/or diseases in the Ingenuity knowledge base were considered for the analysis. Fischer's exact test was used to calculate a P-value determining the probability that each biological function and/or disease assigned to that data set is due to chance alone. Raw microarray data can be accessed from the Gene Expression Omnibus repository (http://www.ncbi.nlm.nih.gov/geo/) with data set accession number GSE16798.
Results
Pirin (PIR) expression is downregulated in acute myeloid leukemia (AML)
On the basis of our previous results, we decided to analyze PIR expression in a larger cohort of AML samples to uncover a Table 1) were screened for PIR mRNA expression and compared with the average expression level in CD34 þ hematopoietic progenitor cells derived from 11 healthy donors. qPCR analysis of these samples revealed a greater than twofold downregulation of PIR mRNA expression in 39/42 AML cases (in 36/42 cases, downregulation was greater than fivefold and in 21/42 cases, the expression was not detectable) and no correlation with FrenchAmerican-British classification subtype or specific genetic alterations (Figure 1a and Supplementary Table 1 ). Downregulation or silencing of PIR expression is, therefore, a common molecular feature in human AML.
Pirin expression was next analyzed in myeloid cells bearing AML fusion proteins to assess whether these model systems reflect our findings in primary AML blasts. We first analyzed U937 cells expressing PML/RAR and AML1/ETO 3 by qPCR and western blot with anti-PIR antibody, and found that both mRNA and protein expression decreased in the presence of the fusion proteins (Figure 1b) . Next, we analyzed PIR levels in primary leukemic blasts derived from the bone marrow of AML mouse models. 15 PIR is expressed at low levels in normal Taken together, our results suggest that PIR transcriptional repression is a very frequent event in AML and leads to a decrease in PIR protein levels in both human and mouse models of the disease.
Pirin (PIR) expression increases during myeloid differentiation of primary hematopoietic cells in vitro
We next analyzed whether PIR expression is modulated during normal myeloid differentiation using human CD34 þ cells and murine LinÀ cells, which represent hematopoietic stem/ progenitor cells. CD34 þ cells were isolated from healthy donors using a positive selection procedure. To induce myelomonocytic differentiation, CD34 þ cells were either grown in liquid culture containing IL-6, SCF, Flt3 ligand, thrombopoietin, G-CSF and GM-CSF for 12 days, with addition of human serum at day 9, or plated in methylcellulose containing IL-6, SCF, GM-CSF, IL-3 and G-CSF for 9 days. PIR expression was assessed at both mRNA and protein levels, and resulted significantly upregulated upon myelomonocytic differentiation (Figures 2a and b) . Maturation was assessed by FACS analysis of CD34 and CD11b expression (Figure 2c ) and by morphology (Figure 2d) .
Lineage minus cells were purified from the bone marrow of wild-type 129SvEv mice by negative selection, and plated in methylcellulose in the presence of G-CSF and GM-CSF to drive myeloid differentiation. After 7 days, cells were harvested, differentiation was assessed by FACS analysis of c-Kit, Mac1 and Gr1 expression (Figure 2e ) and cells were lysed for protein extraction. LinÀ cells grown in liquid culture in the absence of G-CSF and GM-CSF were used as control. Western blot analysis Three independent experiments were performed and the statistical significance of differences between shPIR and control cells were assessed using Student's t-test (**Po0.05; *P ¼ 0.12).
showed significantly higher PIR levels in mature cells than in undifferentiated LinÀ cells (Figure 2f) .
We next analyzed whether PIR levels vary in a model of AML differentiation therapy. For this purpose, we used the RA-sensitive NB4 human cell line, derived from a patient with acute promyelocytic leukemia (APL). Expression of the CD11b surface antigen was measured after 48 h of RA treatment to control NB4 maturation (Figure 2g) . Consistent with the results obtained in normal primary cells, PIR mRNA levels increased approximately threefold upon terminal differentiation (Figure 2h) . The lower-fold increase compared with that observed in primary cells after myelomonocytic maturation is likely due to the fact that NB4 cells are promyelocytes, and therefore already partially differentiated.
Taken together, these data show that PIR expression increases significantly during myeloid maturation of both human and murine hematopoietic cells.
Pirin (PIR) knockdown partially impairs myeloid differentiation of U937 cells
U937 cells differentiate to monocytes in response to treatment with vitamin D3 and transforming growth factor-b. 16 ,17 U937 differentiation can be monitored by measuring the increase in expression of specific surface markers such as CD14. To directly measure the effects of PIR downregulation in myeloid maturation, we performed PIR knockdown experiments in U937 cells. Two different PIR-shRNAs (shPIR 7 and shPIR 4) were cloned in the pSICO-R lentiviral vector that allows for puromycin selection of transduced cells. pSICO-R vector-transfected cells were used as control. Western blot analysis showed that PIR expression was blocked by both PIR-shRNAs with high efficiency (Figure 3a) . CD14 expression was measured using FACS analysis in U937 control cells and in PIR-shRNA-transduced cells after treatment with vitamin D3 and transforming growth factor-b for 24 and 48 h. Control cells behaved similar to wild-type U937 cells (data not shown), suggesting that lentiviral infection does not interfere with the differentiation program. On the contrary, after 24 h of vitamin D3 and transforming growth factor-b treatment, we observed a 55 and 42% decrease in CD14 expression in shPIR 7 and shPIR 4 cells, respectively; after 48 h, the reduction in CD14 expression was of 38% by both shPIR constructs (Figure 3b ). These results suggest that PIR silencing leads to an impairment in terminal maturation of U937 cells and may contribute to the differentiation of block characteristic of AML blasts.
Pirin (PIR) knockdown impairs the ability of LinÀ cells to respond to differentiation stimuli in vitro
The effect of PIR knockdown on myeloid differentiation was also analyzed in primary murine hematopoietic cells. Two shRNAs for the murine PIR homolog (shPIRmm 1 and shPIRmm 5) were cloned into the pSICO-R vector and used to infect LinÀ cells. After puromycin selection, a stable bulk population of cells was obtained for each construct, and western blot analysis revealed a significant reduction of PIR expression in both cases (Figure 4a) . We then performed a clonogenic assay by plating shPIRtransduced LinÀ cells in methylcellulose in the presence of G-CSF and GM-CSF. After 7 days, colonies were scored, cells from replica plates were pooled and differentiation was assessed visually using May-Grumwald-Giemsa staining and immunophenotypically using FACS analysis of Sca-1 and c-Kit, which are characteristic markers of hematopoietic stem/progenitor cells. The number of colonies obtained after G-CSF and GM-CSF treatment was significantly decreased only by shPIRmm 1 (54%), whereas shPIRmm 5 did not lead to a significant variation in colony number (87%) (Figures 4b and c) . In both conditions, however, the size of the colonies was smaller (Figure 4b ). May-GrumwaldGiemsa staining showed that, as opposed to control colonies that show a prevalence of mature myeloid cells (macrophages, promyelocytes and neutrophils), shPIRmm 1 and shPIRmm 5 colonies contain variable proportions of undifferentiated, blastlike cells (18.5 and 13%, respectively), as indicated by morphology, low nucleus/cytoplasm ratio, basophilic staining and lack of cytoplasmic granules (Figures 4d and e) . Representative cells are shown in Supplementary Figure 1 . Furthermore, FACS analysis of surface markers revealed that the proportion of cells expressing c-Kit and Sca-1 increased 3.9-fold and 1.7-fold, respectively, in shPIRmm 1 cells and 1.5-fold in shPIRmm 5, with respect to control cells (Figures 4f and g ).
There are some differences in the specific phenotypes resulting from PIR ablation with the two shRNAs. These may be due to different off-target effects associated with each construct. The probability that two shRNAs yield similar offtarget effects is, however, extremely low; therefore, these results suggest that PIR ablation in LinÀ cells partially impairs the differentiation response to G-CSF and GM-CSF.
Pirin (PIR) knockdown in U937 cells results in increased expression of HOXA genes
We next analyzed the global gene expression profile of U937 cells that do not express PIR, with the aim of identifying genes that may participate in the impairment of terminal differentiation. Total RNA was extracted from U937 cells transduced with shPIR 7 or with the empty pSICO-R vector and hybridized to Affymetrix GeneChip HG-U133 Plus 2.0 arrays as described in Materials and methods. Results were analyzed as previously Pirin downregulation in AML S Licciulli et al described, 3, 18 and regulated genes (more than twofold) were annotated and classified using the Ingenuity pathways analysis software. A total of 492 regulated genes were identified, 305 induced and 187 repressed, after knockdown of PIR protein (Supplementary Table 2 ). The most striking enrichment that emerged from functional classification was the significant upregulation of genes involved in immune response and lymphocyte function (Figure 5a ). However, no downregulation of genes involved in myeloid differentiation was observed (for complete functional classification, see Supplementary Table 3) .
The transcriptional response to PIR silencing may, however, be affected in AML cells by the simultaneous expression of leukemogenic oncogenes. To identify which PIR targets may be of relevance in AML, we searched for genes that are concordantly regulated by both PIR ablation and expression of AML1/ETO or PML/RAR in U937 cells. Previously published data sets 3, 14, 18 were reanalyzed using the same stringency parameters and annotated using Ingenuity pathways analysis. We thus identified 32 common target genes, 5 of which downregulated (including PIR), and 27 upregulated (Table 1) . Functional classification of this list (Supplementary Table 4) revealed seven genes involved in hematopoiesis: 6 upregulated (CXCL11, HOXA5, HOXA9, IL7R, PTPRC and SOX4) and one downregulated (ID1). Interestingly, several of the induced genes are involved in the early phases of hematopoiesis and/or are activated in AML.
Considering their known relevance in myeloid differentiation and leukemogenesis, we further analyzed by qPCR whether other HOXA genes were regulated after PIR silencing. A comparison of HOXA mRNA levels in U937-shPIR 7 or U937-shPIR 4 with U937-pSICO-R confirmed the upregulation of HOXA5 and HOXA9 identified by microarray analysis, and further identified induction of HOXA3, HOXA7 and HOXA13 expression (Figure 5b) .
Taken together, these results suggest that PIR does not modulate the expression of crucial regulators of myeloid differentiation, but may be involved in the repression of genes that are expressed in early hematopoietic progenitor cells.
Discussion
Pirin is a transcriptional regulator previously identified as a target of the AML-associated fusion proteins AML1/ETO and PML/RAR. 3 In this report, we show that PIR expression levels are downregulated or silenced not only in AML with t(8;21) and t (15;17) , but in the vast majority of AML cases, independently of cytogenetic alterations and subtype. To analyze the consequences of PIR silencing in myeloid cells and its possible role in AML, we analyzed the effects of PIR ablation in U937 cells and in primary mouse hematopoietic cells. In both model systems, we observed an impairment of terminal myeloid differentiation, Table 1 Common regulated genes between PIR silencing and expression of PML/RAR or AML1/ETO in U937 cells suggesting that PIR may be required for efficient myeloid maturation. Consistent with this hypothesis, PIR expression increases during myeloid maturation of both human and murine primary hematopoietic precursor cells, and in RA-induced differentiation of an APL cell line. The mechanism through which PIR participates in the process of differentiation is not immediately obvious, considering the diversity of functions so far attributed to PIR. It has been defined as a transcriptional regulator on the basis of its interaction with B-cell chronic lymphocytic leukemia/lymphoma 3 5 and nuclear factor I/CCAAT box transcription factor. 4 We therefore analyzed the transcriptional effects of PIR silencing in U937 cells and did not detect modulation of genes associated with myeloid differentiation. Although this may be due to the cellular model under analysis, expression of AML1/ETO or PML/RAR in the same model system does indeed result in repression of essential regulators of myeloid differentiation, such as genes encoding for the PU.1 and CEBP family of transcriptional regulators. PIR silencing instead results in moderate induction of several genes associated with early hematopoiesis, such as CITED2,
19
CD109,
20 SOX4 21 and importantly, HOXA genes, 22, 23 suggesting that the increase in PIR expression observed during myeloid differentiation may be required for repression of genes associated with stem cell/progenitor functions. PIR may, therefore, be involved in rendering hematopoietic progenitors permissive to the expression of myeloid-specific genes. This view is further supported by the increased transcriptional levels of genes associated with lymphoid commitment and differentiation, such as IL7R, CXCL11 and CD69, observed upon silencing of PIR.
The mechanism through which downregulation of PIR expression is achieved in AML remains to be analyzed. PIR is not a direct transcriptional target of AML1/ETO 14 or PML/RAR (S Licciulli and M Alcalay, unpublished results) and other indirect mechanisms must therefore be responsible for its repression. AML cells, unlike normal human CD34 þ progenitor cells, show activation of NF-kB, 24 and inhibition of NF-kB activity in AML blasts induces cell death. 25 It has been recently shown that NF-kB physically interacts in the cytoplasm with mutated nucleophosmin, which is found in approximately 30% of AML, 26 and that this interaction results in cytoplasmic sequestration of the active form of NF-kB. 27 Concordantly, the absence of nucleophosmin mutations is one of the main characteristics of patients with increased NF-kB activity. Although PIR downregulation was a constant feature in AML in our study, it was less pronounced in samples derived from patients with mutated nucleophosmin. One could therefore speculate that PIR expression may be partially controlled by NF-kB, which is an intriguing possibility in consideration of the putative role of PIR itself in NF-kB regulation.
Our results show that PIR downregulation is a common molecular feature of AML and may be functionally linked with the pathogenesis of the disease.
